Diagnostic Center | June 24, 2025
Merck announces Phase 3 hyperion study of Winrevair met primary endpoint in recently diagnosed adults with PAH
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
